
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5315347/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Mycosis Fungoides and Its Relationship to Atopy, Serum Total IgE, and Eosinophil Counts. Clinical Lymphoma, Myeloma and Leukemia, 2021, 21, 279-288.e7.	0.2	4
2	High-Scatter Lymphocytes in the Blood of Erythrodermic Cutaneous T-Cell Lymphoma: Evidence for Large-Cell Transformation?. Clinical Lymphoma, Myeloma and Leukemia, 2020, 20, 624-631.e2.	0.2	1
3	Evidence linking atopy and staphylococcal superantigens to the pathogenesis of lymphomatoid papulosis, a recurrent CD30+ cutaneous lymphoproliferative disorder. PLoS ONE, 2020, 15, e0228751.	1.1	11
4	Title is missing!. , 2020, 15, e0228751.		0
5	Title is missing!. , 2020, 15, e0228751.		0
6	Title is missing!. , 2020, 15, e0228751.		0
7	Title is missing!. , 2020, 15, e0228751.		0
8	A histoâ€immunopathologic and prognostic study of erythrodermic cutaneous Tâ€cell lymphoma. Journal of Cutaneous Pathology, 2019, 46, 913-924.	0.7	4
9	Prevalence of atopy and staphylococcal superantigenâ€specific immunoglobulin E (IgE) antibodies and total serum IgE in primary cutaneous T―and Bâ€cell lymphoma. Journal of Dermatology, 2019, 46, 1170-1178.	0.6	4
10	Prognostic Significance of Serum Copper in Patients With Cutaneous T-cell Lymphoma. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, 228-238.e4.	0.2	4
11	Pityriasis lichenoides: Longâ€ŧerm followâ€up study. Pediatric Dermatology, 2018, 35, 213-219.	0.5	16
12	CD4+CD26â^'lymphocytes are useful to assess blood involvement and define B ratings in cutaneous T cell lymphoma. Leukemia and Lymphoma, 2018, 59, 330-339.	0.6	18
13	Comment on B ratings for erythrodermic cutaneous T-cell lymphoma. European Journal of Cancer, 2018, 101, 281-283.	1.3	0
14	Prognostic Implications of Blood B Ratings for Erythrodermic Cutaneous T cell Lymphoma. Journal of Clinical & Experimental Dermatology Research, 2018, 09, .	0.1	1
15	Commentary about papular mycosis fungoides, lymphomatoid papulosis and lymphomatoid pityriasis lichenoides: more similarities than differences. Journal of Cutaneous Pathology, 2016, 43, 303-312.	0.7	17
16	Genomic landscape of cutaneous T cell lymphoma. Nature Genetics, 2015, 47, 1011-1019.	9.4	347
17	FoxP3-Positive T-Regulatory Cells in Lymph Nodes with Mycosis Fungoides and Sézary Syndrome. Lymphoma, 2014, 2014, 1-9.	0.2	1
18	Prognostic factors and risk stratification in early mycosis fungoides. Leukemia and Lymphoma, 2014, 55, 44-50.	0.6	23

#	Article	IF	CITATIONS
19	High Soluble CD30, CD25, and IL-6 May Identify Patients with Worse Survival in CD30+ Cutaneous Lymphomas and Early Mycosis Fungoides. Journal of Investigative Dermatology, 2012, 132, 703-710.	0.3	28
20	Lymphomatoid Papulosis Followed by Pityriasis Lichenoides: A Common Pathogenesis?. American Journal of Dermatopathology, 2011, 33, 835-840.	0.3	21
21	Simplified Flow Cytometric Assessment in Mycosis Fungoides and Sézary Syndrome. American Journal of Clinical Pathology, 2011, 136, 944-953.	0.4	60
22	Clinical End Points and Response Criteria in Mycosis Fungoides and Sézary Syndrome: A Consensus Statement of the International Society for Cutaneous Lymphomas, the United States Cutaneous Lymphoma Consortium, and the Cutaneous Lymphoma Task Force of the European Organisation for Research and Treatment of Cancer. Journal of Clinical Oncology, 2011, 29, 2598-2607.	0.8	550
23	Predictors of response to extracorporeal photopheresis in advanced mycosis fungoides and Sézary syndrome. Photodermatology Photoimmunology and Photomedicine, 2010, 26, 182-191.	0.7	22
24	Evaluation of the Long-Term Tolerability and Clinical Benefit of Vorinostat in Patients With Advanced Cutaneous T-Cell Lymphoma. Clinical Lymphoma and Myeloma, 2009, 9, 412-416.	1.4	88
25	CD158k/KIR3DL2 is a useful marker for identifying neoplastic Tâ€cells in Sézary syndrome by flow cytometry. Cytometry Part B - Clinical Cytometry, 2008, 74B, 156-162.	0.7	61
26	Expression of T-plastin, FoxP3 and other tumor-associated markers by leukemic T-cells of cutaneous T-cell lymphoma. Leukemia and Lymphoma, 2008, 49, 1190-1201.	0.6	46
27	Sézary Syndrome Coexisting with B-Cell Chronic Lymphocytic Leukemia: Case Report and Review of the Literature. Dermatology, 2008, 216, 68-75.	0.9	11
28	Revisions to the staging and classification of mycosis fungoides and Sézary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC). Blood, 2007, 110, 1713-1722.	0.6	1,243
29	Chemokine Receptor Expression by Leukemic T Cells of Cutaneous T-Cell Lymphoma: Clinical and Histopathological Correlations. Journal of Investigative Dermatology, 2007, 127, 2882-2892.	0.3	26
30	Erythrodermic cutaneous T cell lymphoma with hypereosinophilic syndrome: Treatment with interferon alfa and extracorporeal photopheresis. International Journal of Dermatology, 2007, 46, 1198-1204.	0.5	13
31	Sézary cell counts in erythrodermic cutaneous T-cell lymphoma: Implications for prognosis and staging. Leukemia and Lymphoma, 2006, 47, 1841-1856.	0.6	66
32	Papular mycosis fungoides: A variant of mycosis fungoides or lymphomatoid papulosis?. Journal of the American Academy of Dermatology, 2006, 55, 177-180.	0.6	16
33	On the diagnosis of erythrodermic cutaneous T-cell lymphoma. Journal of Cutaneous Pathology, 2006, 33, 27-42.	0.7	61
34	Multicolor fluorescence in situ hybridization (SKY) in mycosis fungoides and Sézary syndrome: Search for recurrent chromosome abnormalities. Genes Chromosomes and Cancer, 2006, 45, 383-391.	1.5	49
35	Evidence for Restricted Vβ Usage in the Leukemic Phase of Cutaneous T Cell Lymphoma. Journal of Investigative Dermatology, 2005, 124, 651-661.	0.3	39
36	Defining early mycosis fungoides. Journal of the American Academy of Dermatology, 2005, 53, 1053-1063.	0.6	453

#	Article	IF	CITATIONS
37	Treatment planning in cutaneous T-Cell lymphoma. Dermatologic Therapy, 2003, 16, 276-282.	0.8	12
38	The Sézary syndrome: hematologic criteria. Hematology/Oncology Clinics of North America, 2003, 17, 1367-1389.	0.9	66
39	Classification and Prediction of Survival in Patients with the Leukemic Phase of Cutaneous T Cell Lymphoma. Journal of Experimental Medicine, 2003, 197, 1477-1488.	4.2	174
40	Improved Sensitivity of T-Cell Clonality Detection in Mycosis Fungoides by Hand Microdissection and Heteroduplex Analysis. Archives of Dermatology, 2003, 139, 1571-5.	1.7	12
41	Update on erythrodermic cutaneous T-cell lymphoma: Report of the international society for cutaneous lymphomas. Journal of the American Academy of Dermatology, 2002, 46, 95-106.	0.6	448
42	Infrequent Fas Mutations but No Bax or p53 Mutations in Early Mycosis Fungoides: A Possible Mechanism for the Accumulation of Malignant T Lymphocytes in the Skin. Journal of Investigative Dermatology, 2002, 118, 949-956.	0.3	89
43	Treatment of Cutaneous T Cell Lymphoma: 2001. Recent Results in Cancer Research, 2002, 160, 309-320.	1.8	10
44	Increased interleukin 5 production in eosinophilic S?zary syndrome: Regulation by interferon alfa and interleukin 12. Journal of the American Academy of Dermatology, 2001, 44, 28-32.	0.6	176
45	Variable CD7 Expression on T Cells in the Leukemic Phase of Cutaneous T Cell Lymphoma (Sézary) Tj ETQq1	1 0.784314 0.3	1 rgBT /Overlo
46	Fine-Needle Aspiration Biopsy in the Evaluation of Lymphadenopathy Associated With Cutaneous T-Cell Lymphoma (Mycosis Fungoides/Sézary Syndrome). American Journal of Clinical Pathology, 2000, 113, 865-871.	0.4	52
47	Mycosis Fungoides With CD30-Positive Cells in the Epidermis. American Journal of Dermatopathology, 2000, 22, 212-216.	0.3	34
48	The Prognostic Significance of Delayed Hypersensitivity to Dinitrochlorobenzene and Mechlorethamine Hydrochloride in Cutaneous T Cell Lymphoma. Journal of Investigative Dermatology, 1998, 110, 946-950.	0.3	15
49	Radiotherapy for unilesional mycosis fungoides. International Journal of Radiation Oncology Biology Physics, 1998, 42, 361-364.	0.4	93
50	The Potential Therapeutic Role of Interleukin-12 in Cutaneous T-Cell Lymphoma. Annals of the New York Academy of Sciences, 1996, 795, 310-318.	1.8	37
51	The Same Dominant T Cell Clone Is Present in Multiple Regressing Skin Lesions and Associated T Cell Lymphomas of Patients with Lymphomatoid Papulosis. Journal of Investigative Dermatology, 1996, 106, 696-700.	0.3	121
52	Lymph node classification systems in cutaneous T-cell lymphoma. Evidence for the utility of the working formulation of non-Hodgkin's lymphomas for clinical usage. Cancer, 1994, 73, 207-218.	2.0	50
53	Extracorporeal Photopheresis and Recombinant Interferon Alfa 2b in Sezary Syndrome. American Journal of Clinical Oncology: Cancer Clinical Trials, 1994, 17, 255-263.	0.6	55
54	Home UV phototherapy of early mycosis fungoides: Long-term follow-up observations in thirty-one patients. Journal of the American Academy of Dermatology, 1993, 29, 73-77.	0.6	73

#	Article	IF	CITATIONS
55	Mycosis Fungoides of the Larynx. Otolaryngology - Head and Neck Surgery, 1992, 107, 120-123.	1.1	6
56	Lymph Node Histopathologic Findings in Cutaneous T-Cell Lymphoma: <i>A Prognostic Classification System Based on Morphologic Assessment</i> . American Journal of Clinical Pathology, 1992, 97, 121-129.	0.4	28
57	Aberrant Cytokine Production By Sezary Syndrome Patients: Cytokine Secretion Pattern Resembles Murine Th2 Cells. Journal of Investigative Dermatology, 1992, 99, 90-94.	0.3	223
58	Risk of second malignancy after cutaneous T-cell lymphoma. Cancer, 1989, 63, 1612-1615.	2.0	120
59	Long-term efficacy, curative potential, and carcinogenicity of topical mechlorethamine chemotherapy in cutaneous T cell lymphoma. Journal of the American Academy of Dermatology, 1989, 20, 416-428.	0.6	246
60	Natural Cell-Mediated Cytotoxicity in Cutaneous T-Cell Lymphomas. Journal of Investigative Dermatology, 1983, 81, 176-178.	0.3	10
61	Clonal Characteristics of Cutaneous T Cell Lymphomas: Cytogenetic Evidence from Blood, Lymph Nodes, and Skin. Journal of Investigative Dermatology, 1982, 78, 69-75.	0.3	76
62	Prognostic significance of cytomorphology in the cutaneous t-cell lymphomas. Cancer, 1981, 47, 119-125.	2.0	39
63	Mycosis fungoides, nitrogen mustard and skin cancer. British Journal of Dermatology, 1978, 99, 61-63.	1.4	74
64	Frequent low doses of intravenous mechlorethamine for late-stage mycosis fungoides lymphoma. Cancer, 1975, 36, 1613-1618.	2.0	25